CD59 Primary Antibody
|Aliases||1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human CD59 (AA: 31-111) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|ICC (Immunocytochemistry)||1/50 - 1/200|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using CD59 mAb against human CD59 recombinant protein. (Expected MW is 34.7 kDa)
Figure 2: Western blot analysis using CD59 mAb against HEK293 (1) and CD59 (AA: 31-111)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 3: Immunofluorescence analysis of MCF-7 cells using CD59 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Figure 4: Immunofluorescence analysis of Hela cells using CD59 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Figure 5: Flow cytometric analysis of HeLa cells using CD59 mouse mAb (green) and negative control (red).
Figure 6: Immunohistochemical analysis of paraffin-embedded bladder cancer tissues using CD59 mouse mAb with DAB staining.
Figure 7: Immunohistochemical analysis of paraffin-embedded esophageal cancer tissues using CD59 mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
|Description||This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. |
|References (references)||1.Cell Immunol. 2010;265(2):127-32. |
2.Chin Med J (Engl). 2009 Sep 20;122(18):2123-8.